Broad Spectrum AI Designed Antibiotics for AMR
AINovo has used our proprietary AI platform to design novel biologic therapeutics which show broad-spectrum activity against clinical strains of AMR pathogens.
AI-designed molecules show broad spectrum activity for AMR Pathogens in vitro, synergy with existing antibiotics, variety of formulations possible
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial compound/strategy
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- BSI
- RTI
- SSTI
- SSI
- UTI
- STI
- GII
- CNSI
- IAI
Geographic origin:
- North America
- South America
- Eurasia
- Africa
- Oceania
N.A.
AINovo has developed a proprietary artificial intelligence platform to design protein-based medicines &diagnostics for oncology & infectious diseases.
Partnerships with biopharma and research institutions for further development of our AMR assets, Technology-based partnerships with biopharma for joint development of novel molecules through AINovo Biotech’s artificial intelligence platform